Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts.

[1]  Tyler T. Risom,et al.  Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma , 2021, Cell.

[2]  P. Kristel,et al.  Genomic profiling defines variable clonal relatedness between invasive breast cancer and primary ductal carcinoma in situ , 2021, medRxiv.

[3]  K. Chin,et al.  Genomic Alterations during the In Situ to Invasive Ductal Breast Carcinoma Transition Shaped by the Immune System , 2020, Molecular Cancer Research.

[4]  Tonje G. Lien,et al.  Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions , 2020, npj Breast Cancer.

[5]  K. Polyak,et al.  Immune Escape during Breast Tumor Progression , 2020, Cancer Immunology Research.

[6]  J. Reis-Filho,et al.  Whole-Exome Sequencing Analysis of the Progression from Non–Low-Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma , 2020, Clinical Cancer Research.

[7]  Ruud H. Brakenhoff,et al.  ACE: absolute copy number estimation from low-coverage whole-genome sequencing data , 2019, Bioinform..

[8]  L. Shevde,et al.  The Tumor Microenvironment Innately Modulates Cancer Progression. , 2019, Cancer research.

[9]  Ash A. Alizadeh,et al.  Determining cell-type abundance and expression from bulk tissues with digital cytometry , 2019, Nature Biotechnology.

[10]  Bin Liu,et al.  Dynamics of breast cancer relapse reveal late recurring ER-positive genomic subgroups , 2019, Nature.

[11]  Jianxin Wang,et al.  BPG: Seamless, automated and interactive visualization of scientific data , 2019, BMC Bioinformatics.

[12]  R. West,et al.  Gene expression profiling of single cells from archival tissue with laser-capture microdissection and Smart-3SEQ , 2017, Genome Research.

[13]  Arnoldo Frigessi,et al.  A Bayesian Two-Way Latent Structure Model for Genomic Data Integration Reveals Few Pan-Genomic Cluster Subtypes in a Breast Cancer Cohort , 2018, bioRxiv.

[14]  Ambrose J. Carr,et al.  Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment , 2018, Cell.

[15]  Jesper Eisfeldt,et al.  Sarek: A portable workflow for whole-genome sequencing analysis of germline and somatic variants , 2018, bioRxiv.

[16]  Adrian V. Lee,et al.  An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics , 2018, Cell.

[17]  Mary E. Edgerton,et al.  Multiclonal Invasion in Breast Tumors Identified by Topographic Single Cell Sequencing , 2018, Cell.

[18]  T. Sørlie,et al.  Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. , 2017, Cancer discovery.

[19]  T. Sørlie,et al.  Molecular Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast Cancer. , 2016, Cell reports.

[20]  Joel S. Parker,et al.  Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer , 2016, Bioinform..

[21]  A. Sahin,et al.  A Molecular Portrait of High-Grade Ductal Carcinoma In Situ. , 2015, Cancer research.

[22]  Kylie L. Gorringe,et al.  Copy number analysis of ductal carcinoma in situ with and without recurrence , 2015, Modern Pathology.

[23]  Piet Demeester,et al.  FlowSOM: Using self‐organizing maps for visualization and interpretation of cytometry data , 2015, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[24]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[25]  George W. Sledge,et al.  A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast , 2013, Journal of the National Cancer Institute.

[26]  Serafim Batzoglou,et al.  Genome evolution during progression to breast cancer , 2013, Genome research.

[27]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[28]  A. Schäffer,et al.  Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression. , 2012, The American journal of pathology.

[29]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[30]  Samantha E. Boyle,et al.  Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma , 2012, Breast Cancer Research and Treatment.

[31]  G. Getz,et al.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.

[32]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[33]  A. Krasnitz,et al.  Genomic Architecture Characterizes Tumor Progression Paths and Fate in Breast Cancer Patients , 2010, Science Translational Medicine.

[34]  Karla Kerlikowske,et al.  Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. , 2010, Journal of the National Cancer Institute.

[35]  J. Thiery,et al.  Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma In situ of the Breast , 2008, Clinical Cancer Research.

[36]  A. Vincent-Salomon,et al.  Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues , 2007, Journal of Clinical Pathology.

[37]  Wessel N. van Wieringen,et al.  CGHcall: calling aberrations for array CGH tumor profiles , 2007, Bioinform..

[38]  Jun Yao,et al.  Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. , 2006, Cancer research.

[39]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[40]  S. Devries,et al.  Patterns of Chromosomal Alterations in Breast Ductal Carcinoma In situ , 2004, Clinical Cancer Research.

[41]  Rameen Beroukhim,et al.  Molecular characterization of the tumor microenvironment in breast cancer. , 2004, Cancer cell.

[42]  M. Gnant,et al.  High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[43]  Pablo Tamayo,et al.  Metagenes and molecular pattern discovery using matrix factorization , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[44]  R. Salunga,et al.  Gene expression profiles of human breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[45]  M. Fernö,et al.  Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. , 2001, European journal of cancer.

[46]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[47]  C. Osborne,et al.  HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.